Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
zhinao capsule
- Development stage
- Unknown
- Lead developer
- First Affiliated Hospital of Anhui University of Chinese Medicine
- Administration
- Oral
01
Overview
Zhinao capsule is a traditional Chinese medicine (TCM) formulation developed by the First Affiliated Hospital of Anhui University of Traditional Chinese Medicine for the treatment of Alzheimer's disease (AD) and related cognitive and sleep disorders. It is a multi-component preparation composed of eight herbal and animal-derived ingredients: Codonopsis pilosula, Astragalus membranaceus, Polygonatum sibiricum, Cistanche deserticola, Curcuma wenyujin, Acorus tatarinowii, Ligusticum chuanxiong, and Pheretima aspergillum. The capsule exerts neuroprotective effects through multiple pathways, including the modulation of the cAMP/PKA/CREB signaling pathway, inhibition of neuroinflammation (by reducing levels of TNF-α, IL-6, and IL-1β), and reduction of amyloid-beta (Aβ) deposition. Additionally, it has been shown to promote neurogenesis and enhance synaptic plasticity by upregulating brain-derived neurotrophic factor (BDNF) and synaptic proteins such as synaptophysin and PSD-95. Zhinao capsule is approved as a hospital preparation in Anhui Province and has undergone clinical evaluation for mild to moderate Alzheimer's disease.
- Brand names
- Zhinao Capsule
- Other names
- Zhinao
02
Targets
CREB (Cyclic AMP response element-binding protein)CASP3 (Caspase-3)GFAP (Glial fibrillary acidic protein)IL1B (Interleukin-1 beta)IL-6 (Interleukin 6)TNFA (Tumor necrosis factor alpha (soluble))VEGFA (Vascular endothelial growth factor A)PKA (Cyclic amp-dependent protein kinase)Aβ (Amyloid-beta peptides and aggregates)
Beyond the preview
Go deeper on zhinao capsule.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on zhinao capsule.